Price
No data yet.
Social Signal Score
Revenue
$16.46B+830.99%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ge Li
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 33,834
- Beta
- -0.03
- Country
- CN
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 12.11
Financials
Revenue
$16.46B+831.0%Net Income
$6.43B+1808.4%EBITDA
$8.80B+1827.6%Free Cash Flow
$4.34BEPS (diluted)
$2.17+1346.7%Shares Outstanding (diluted)
14.15M-99.4%Operating Expenses
$-178.82MCash & Debt
$46.66BReturn of Capital
$4.74BDividend per Share
$0.08Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $45.46B | $19.15B | $6.75 |
| 2024 | $39.24B | $9.45B | $3.28 |
| 2023 | $40.34B | $9.61B | $3.24 |
| 2022 | $39.35B | $8.81B | $3.01 |
| 2021 | $22.90B | $5.10B | $1.75 |
| 2020 | $16.54B | $2.96B | $1.06 |
| 2019 | $12.87B | $1.85B | $0.68 |
| 2018 | $9.61B | $2.26B | $0.95 |
| 2017 | $7.77B | $1.23B | $0.56 |
| 2016 | $6.12B | $974.98M | $0.46 |
| 2015 | $4.88B | $348.97M | $0.17 |
| 2014 | $4.14B | $461.50M | $0.22 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from WUXAY's reported EPS growth of 36.5% a year over 11 years. Historical EPS growth of 37% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $25.07
- Implied price
- $325.94
- Return from $27.17
- 64.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $162.05 — today's price is already 83.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| 20.0% | 41.0% | 46.7% | 51.7% | 56.1% | 60.1% |
| 25.0% | 46.8% | 52.9% | 58.0% | 62.6% | 66.8% |
| 30.0% | 52.7% | 59.0% | 64.4% | 69.1% | 73.4% |
| 35.0% | 58.6% | 65.1% | 70.7% | 75.6% | 80.1% |
| 40.0% | 64.5% | 71.2% | 77.0% | 82.1% | 86.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+17.65%Social Signal Score
Mentions (3)
- Newsprnewswire.com·36d ago·Neutral
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion SHANGHAI, Aug. 30, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend.
View source ↗ - Newszacks.com·39d ago·Negative
Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
View source ↗ - Newszacks.com·55d ago·Negative
Here's Why Momentum in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Should Keep going Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $0.38 per share
Typical surprise +26.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Oct 5$0.32 vs $0.23beat
- Mon, Apr 27$0.23 vs $0.18beat
- Mon, Mar 23$0.37 vs $0.38miss
- Fri, Oct 31$0.17 vs $0.15beat
- Mon, Jul 28$0.24 vs $0.19beat
- Mon, Apr 28$0.18 vs $0.11beat
Estimates and results for WUXAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in WUXAY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.